Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Velocimed Inc.

Division of Abbott Laboratories Inc.
www.velocimed.com

Latest From Velocimed Inc.

Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy

The second company in the US looking to replace certain sinus surgeries with interventional procedures, Entellus is looking to further advance this technology by moving treatment from the OR to the doctor's office.
Medical Device United States

Migraine: Can Devices Spell Relief

As many as half of severe migraine sufferers do not achieve adequate relief with prescription drug therapy, and many of these patients may be candidates for emerging device treatments for migraine. Sales of migraine drugs in the U.S. total more than $2 billion per year, but some analysts believe that the potential market for device-based treatment may be even larger. The question at the moment is whether the devices in development can produce the kind of results that migraine patients are looking for. Clinical trials are currently underway on a number of fronts, and based on early data, the answer looks promising.
Medical Device Clinical Trials

Reviewing 2005: The Top Medical Device Stories

The device industry was robust in 2005. Share prices remain strong for the most part--some orthopedics and cardiovascular companies struggled, but for the most part device stock indices continue strong--and the IPO window for start-ups remains open. New technology is flowing and so are venture dollars. Certainly, the device industry has had few instances of the kinds of bad news that Big Pharma and biotechs have struggled with: investor frustration, high-profile pipeline problems, and general industry struggles to find a viable long-term strategy, with a couple of exceptions. The battle for Guidant was widely-reported precisely because Guidant ran into problems with its ICD line, which caused Johnson & Johnson to hesitate and opened the door for a rival bid from Boston Scientific. Similarly, conflict of interest stories were featured in several general business publications, all with a decidedly negative spin. We don't share the view that conflict of interest is a real problem-just the opposite: physician involvement in device development is the lifeblood of the industry.
Leadership Platform Technologies

What's Hot in Cardiology beyond DES? Try Structural Heart Disease

Structural heart disease was prominently featured during the Emerging Technologies Symposium held during this year's Summer in Seattle cardiovascular conference.
Medical Device Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Contact Info
  • Velocimed Inc.
    Phone: (763) 463-4700
    11400 73rd Ave. N, Ste. 134
    Minneapolis, MN 55369
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register